Beam Therapeutics EV/EBITDA
Qual é o EV/EBITDA de Beam Therapeutics?
O EV/EBITDA de Beam Therapeutics Inc. é N/A
Qual é a definição de EV/EBITDA?
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de empresas na Setor Health Care em NASDAQ em comparação com Beam Therapeutics
O que Beam Therapeutics faz?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Empresas com ev/ebitda semelhantes a Beam Therapeutics
- Castile Resources tem EV/EBITDA de N/A
- Greenhill & Co Inc tem EV/EBITDA de N/A
- Cool Link () tem EV/EBITDA de N/A
- Syntonic tem EV/EBITDA de N/A
- Merida Minerals Inc tem EV/EBITDA de N/A
- Golden Meditech tem EV/EBITDA de N/A
- Beam Therapeutics tem EV/EBITDA de N/A
- Hummingbird Resources Plc tem EV/EBITDA de N/A
- Tern Plc tem EV/EBITDA de N/A
- Magnis Resources tem EV/EBITDA de N/A
- Fastly Inc tem EV/EBITDA de N/A
- Soliton tem EV/EBITDA de N/A
- WeTrade tem EV/EBITDA de N/A